Mr. Schmertzler has served as a member of our Board since 2001 and as Chair of our Board since 2004. Mr. Schmertzler served as a director of our UK subsidiary until February 2016. Since 2008, he has been an Adjunct Professor and Lecturer in Economics at Yale University and, since 2018, a Visiting Professor at Yale NUS in Singapore. Mr. Schmertzler also serves as a Charter Trustee of the Phillips Academy Andover. Mr. Schmertzler currently also serves as Executive Chairman of SHY Therapeutics, a private biotechnology company, as Executive Chairman of Berryville Holdings and Disepl LLC, private cyber-technology companies, and as a Director of AgNovos, a private biotechnology company. From 2001 to 2015, Mr. Schmertzler served as a Managing Director of Aries Advisors, LLC, the sub-advisor to Credit Suisse First Boston Equity Partners, L.P., a private equity fund, and the Chair of the investment committee of Credit Suisse First Boston Equity Partners, L.P. From 1997 to 2001, Mr. Schmertzler was Co-Head of United States and Canadian Private Equity at Credit Suisse First Boston, an investment banking firm. Prior to 1997, Mr. Schmertzler held various management positions with Morgan Stanley and its affiliates, including President of Morgan Stanley Leveraged Capital Funds and founding Managing Director of Morgan Stanley’s biotechnology pharmaceuticals group, and was Managing Director and Chief Financial Officer of Lehman Brothers Kuhn Loeb and Head of International Sales and Trading and Investment Banking at its successor, Lehman Brothers, both investment banking firms. Mr. Schmertzler recently served as a court-appointed director of Lehman Commercial Paper Incorporated, the largest liquidating post bankruptcy subsidiary of Lehman Brothers Holdings, Incorporated. Mr. Schmertzler also previously served as a member of the board of directors of Cytokinetics, Inc., and Idenix Pharmaceuticals, Inc., both of which were at the time public biopharmaceutical companies. Mr. Schmertzler received a B.A. from Yale College in Molecular Biophysics and Biochemistry, History and City Planning and an M.B.A. from the Harvard Business School.
What is Michael Schmertzler's net worth?
The estimated net worth of Michael Schmertzler is at least $4.69 million as of January 8th, 2024. Mr. Schmertzler owns 115,266 shares of PTC Therapeutics stock worth more than $4,686,716 as of October 31st. This net worth approximation does not reflect any other assets that Mr. Schmertzler may own. Learn More about Michael Schmertzler's net worth.
How do I contact Michael Schmertzler?
Has Michael Schmertzler been buying or selling shares of PTC Therapeutics?
Michael Schmertzler has not been actively trading shares of PTC Therapeutics during the past quarter. Most recently, Michael Schmertzler sold 1,500 shares of the business's stock in a transaction on Monday, January 8th. The shares were sold at an average price of $27.81, for a transaction totalling $41,715.00. Following the completion of the sale, the director now directly owns 115,266 shares of the company's stock, valued at $3,205,547.46. Learn More on Michael Schmertzler's trading history.
Who are PTC Therapeutics' active insiders?
PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Pierre Gravier (CFO), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Emma Reeve (Director), Michael Schmertzler (Director), David Southwell (Director), Dawn Svoronos (Director), Christine Utter (CAO), Alethia Young (Chief Financial Officer, Bicycle Therapeutics), and Jerome Zeldis (Director). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?
During the last twelve months, PTC Therapeutics insiders bought shares 1 times. They purchased a total of 7,700 shares worth more than $198,737.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 56,906 shares worth more than $1,787,917.16. The most recent insider tranaction occured on July, 16th when CFO Pierre Gravier sold 2,269 shares worth more than $77,191.38. Insiders at PTC Therapeutics own 5.5% of the company.
Learn More about insider trades at PTC Therapeutics. Information on this page was last updated on 7/16/2024.